Search
A new approach for treating melanoma combines the immunotherapy drug ipilimumab with chemotherapy that treats only the area affected by cancer.
Our recent research demonstrates that the thrombopoietin receptor agonist romiplostim effectively modifies chemotherapy-induced thrombocytopenia (CIT) in solid tumor patients, allowing a majority to resume chemotherapy
Learn about new findings regarding how inherited and acquired genetic mutations cause breast cancer resistance to certain therapies.
Two pivotal studies published in the New England Journal of Medicine and conducted by Memorial Sloan Kettering researchers offer proof of better treatment options for patients with advanced renal cell carcinoma (RCC), the most common form of kidney cancer.
Catch up with some of the patients we got to know in 2017.
At Memorial Sloan Kettering Cancer Center, more than half of patients with gallbladder cancer are diagnosed incidentally following elective cholecystectomy for assumed benign disease. The traditional treatment approach for these patients is re-resection to achieve a cure.
Medical oncologist Mark Kris discusses how new guidelines for preventing nausea and vomiting due to treatment can improve quality of life for people with cancer.
Memorial Sloan Kettering’s annual seminar exposes high school students and their teachers to cutting-edge scientific research.